Sultopride Hydrochloride|CAS 23694-17-9|DC Chemicals

Cas No.:	23694-17-9
Chemical Name:	Sultopride hydrochloride
Synonyms:	N-((1-Ethylpyrrolidin-2-yl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide hydrochloride;Sultopride Hydrochloride;SULTOPRIDE.HCL;N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulphonyl)-2-methoxybenzamide hydrochloride;Sultopride hydrochloride;N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide Monohydrochloride;AS-16926;AC-4565;LIN-1418 hydrochloride;NS00084071;N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxy-benzamide; hydron; chloride;Sultopride hydrochloride [JAN];EINECS 245-829-0;CHEMBL3182384;NS00088055;NCGC00185771-01;DTXCID1028996;8Q6926T32J;N-(1-ETHYL-2-PYRROLIDINYLMETHYL)-2-METHOXY-5-(ETHYLSULFONYL)BENZAMIDE HYDROCHLORIDE;SCHEMBL1417863;CS-0040603;NCGC00184999-01;N-[(1-ethylpyrrolidin-2-yl)methyl]-5-ethylsulfonyl-2-methoxybenzamide;hydrochloride;A816850;BENZAMIDE, N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXY-, MONOHYDROCHLORIDE;Sultopride HCl;Sultopride hydrochloride (JAN);Barnetil (TN);N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulphonyl)-2-methoxybenzamide monohydrochloride;Tox21_113625;23694-17-9;Sultopride monohydrochloride;Tox21_113626;Q27270888;J-015185;sultopride hydrochloride;N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXYBENZAMIDE HYDROCHLORIDE;DTXSID0049070;HY-42849A;Sultopride hydrochloride (LIN-1418 hydrochloride);Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-, hydrochloride (1:1);CAS-23694-17-9;N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulphonyl)-2-methoxybenzamide hydrochloride;BENZAMIDE, N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-2-METHOXY-, HYDROCHLORIDE (1:1);EX-A3336;FT-0659859;SultoprideHCl;Barnotil;D02208;UNII-8Q6926T32J;SULTOPRIDE HYDROCHLORIDE [MI];O-ANISAMIDE, N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-(ETHYLSULFONYL)-, MONOHYDROCHLORIDE;AKOS016010186;SULTOPRIDE HYDROCHLORIDE [WHO-DD]
SMILES:	O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(CC)=O)=CC=C2OC.Cl
Formula:	C₁₇H₂₆N₂O₄S^.HCl
M.Wt:	390.92528
Purity:	>98%
Sotrage:	0°C (short term), -20°C (long term), desiccated

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.